Organization
Perelman School of Medicine
38 abstracts
Abstract
Evaluating the diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial.Org: Department of Neurosurgery, Prince of Wales Hospital, Department of Radiation Oncology, Baptist Health South Florida, Perelman School of Medicine, Department of Radiology,
Abstract
National implementation of an AI-based virtual dietitian for patients with cancer.Org: Savor Health LLC., Perelman School of Medicine, The University of North Carolina at Chapel Hill,
Abstract
BE-a-PAL: A cluster-randomized trial of algorithm-based default palliative care referral among patients with advanced cancer.Org: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, Perelman School of Medicine at the University of Pennsylvania, Tennessee Oncology, PLLC,
Abstract
Real-world and clinical trial validation of a deep learning radiomic biomarker for PD-(L)1 immune checkpoint inhibitor response in stage IV NSCLC.Org: Onc.AI, Pfizer Inc., Department of Radiation Oncology and Radiology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital,
Abstract
The landscape of the intestinal microbiome amongst patients with newly diagnosed invasive breast cancer (BC) and ductal carcinoma in situ (DCIS).Org: Dana-Farber Cancer Institute, Department of Biostatistics & Data Science, Microbiome Analysis Core, Harvard T.H. Chan School of Public Health, Harvard Medical School,
Abstract
Post-market study requirements and associations with timely submission and regulatory action for oncology drugs receiving accelerated approval, 2011-2023.Org: University of Pennsylvania, University of Pennsylvania Perelman School of Medicine, Perelman School of Medicine, Carey Law School,
Abstract
Deciphering pediatric low-grade glioma trajectories: Deep learning–based volumetrics for patients under surveillance.Org: Brigham and Women's Hospital, Division of Neuroradiology, Perelman School of Medicine, University of Pennsylvania, Department of Radiology,
Abstract
Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.Org: Princess Margaret Cancer Centre, Wakayama Medical University, Wakayama, Japan, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Jilin Cancer Hospital, Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research,
Abstract
Real-world outcomes of osimertinib (Osi) vs. afatinib or erlotinib in patients with classical vs. atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC).Org: Penn Medicine Abramson Cancer Center, Perelman School of Medicine,
Abstract
Human-AI teams to improve accuracy and timeliness of oncology trial prescreening: Preplanned interim analysis of a randomized trial.Org: Perelman School of Medicine, University of Pennsylvania, Perelman School of Medicine at the University of Pennsylvania, University of Pennsylvania Perelman School of Medicine,
Abstract
Predictors of mood-related psychiatric disorders after cancer diagnosis.Org: Hospital of the University of Pennsylvania, Perelman School of Medicine, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Epidemiology Laboratory, Clinical Research, and Community Health, Faculty of Medicine, Pharmacy and Dental Medicine of Fez, University of Sidi Mohamed Ben Abdellah, Fez, Morocco, Informatics,
Abstract
Brain metastases in patients with pleural mesothelioma receiving dual checkpoint blockade compared to single-agent checkpoint blockade or chemotherapy.Org: Hospital of the University of Pennsylvania, Perelman School of Medicine, Penn Medicine at Lancaster General Health, University of Pennsylvania, Abramson Cancer Center,
Abstract
Association between state Medicaid policies and accrual of Black and Hispanic patients to cancer clinical trials.Org: Perelman School of Medicine, University of Pennsylvania, Weill Medical College, Cornell University, Medidata AI,
Abstract
Patient- and clinician-directed implementation strategies to improve serious illness communication for high-risk patients with cancer: A cluster-randomized pragmatic trial.Org: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, School of Nursing, University of Alabama at Birmingham, Birmingham, AL, Mailman School of Public Health, Columbia University,
Abstract
Assessment of electronic health record (EHR) –based machine learning (ML) in predicting risk of brain metastasis among patients with early-stage non–small-cell lung cancer (eNSCLC).Org: ConcertAI, Cambridge University Hospitals NHS Foundation Trust, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA,
Abstract
Long-term follow-up of “adjuvant” pembrolizumab following locally ablative therapy for oligometastatic non-small cell lung cancer.Org: University of Pennsylvania, Abramson Cancer Center, Penn Presbyterian Medical Center, Perelman School of Medicine,
Abstract
Clinical pathways innovation: A lesson on the value of clinician based feedback and collaboration with Flatiron Health.Org: Memorial Sloan Kettering Cancer Center, Flatiron Health, San Francisco, CA, Perelman School of Medicine,
Abstract
End-of-life spending analysis of randomized trial of machine learning nudges to prompt serious illness communication among patients with cancer.Org: Perelman School of Medicine, University of Pennsylvania, Ascension Health, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Dana-Farber Cancer Institute,
Abstract
Association of remote, longitudinal patient-reported outcomes (PROs) and step counts with hospitalization or death among patients with advanced cancer undergoing chemotherapy: Secondary analysis of the PROStep randomized trial.Org: Perelman School of Medicine, University of Pennsylvania, Hospital of the University of Pennsylvania, Penn Medicine at Lancaster General Health, Ascension Health,
Abstract
Core biopsy (bx) accuracy and safety of biopsy and preoperative immunotherapy in predicting histological subtype and nuclear grade in ECOG-ACRIN EA8143 perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) undergoing nephrectomy.Org: Perelman School of Medicine, University of Pennsylvania, Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center,
Abstract
Association of participation in Medicare’s Oncology Care Model with spending, utilization, and quality outcomes among commercially insured and Medicare Advantage members: A national difference-in-differences analysis.Org: Memorial Sloan Kettering Cancer Center, Elevance Health, Humana, CVS Health, Texas A&M University,
Abstract
AI-based radiomic biomarkers to predict PD-(L)1 immune checkpoint inhibitor response within PD-L1 high/low/negative expression categories in stage IV NSCLC.Org: H. Lee Moffitt Cancer Center and Research Institute, Onc.AI, Ohio State University Comprehensive Canvcer Hospital, University of Rochester Medical Center Department of Neurobiology and Anatomy, Earle A Chiles Research Institute,
Abstract
Phase 1 study of tasquinimod, an S100A9 inhibitor, alone and in combination with IRd for relapsed and refractory multiple myeloma (RRMM).Org: Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, The Wistar Institute, Active Biotech,
Abstract
Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1.Org: Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Vrije Universiteit Amsterdam, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania,
Abstract
Phase II trial of consolidation pembrolizumab (pembro) after proton reirradiation (re-RT) for thoracic recurrences of non-small cell lung cancer (NSCLC).Org: University of Pennsylvania, Philadelphia, PA, PainReform, CVS Health, Perelman School of Medicine,
Abstract
Implementation strategies for monitoring adherence in real time (iSMART): A pilot randomized trial.Org: Perelman School of Medicine, University of Pennsylvania, Memora Health, University of Florida Department of Health Outcomes and Biomedical Informatics,
Abstract
Electronic health record (EHR)-based machine learning (ML) to predict disease recurrence after surgical resection of early-stage non-small cell lung cancer (eNSCLC).Org: ConcertAI, Perelman School of Medicine, University of Pennsylvania,
Abstract
Evaluating clinical trial inclusion/exclusion criteria from claims using generative artificial intelligence.Org: ConcertAI, Perelman School of Medicine, University of Pennsylvania,
Abstract
Brentuximab vedotin + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort.Org: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, University of Colorado Denver Anschutz Medical Center, Aurora, CO,
Abstract
Racial disparities in germline testing among men with pancreas, breast and metastatic prostate cancers in two health systems.Org: University of Pennsylvania-Abramson Cancer Center, VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, VA Salt Lake City Health Care, University of Pennsylvania,
Abstract
The COVID-19 pandemic's impact on diagnosis of cancers detectable through screening.Org: Perelman School of Medicine, University of Pennsylvania, Abramson Cancer Center, University of Pennsylvania-Abramson Cancer Center,
Abstract
Electronic health record (EHR) and genomics-based machine learning (ML) to predict therapeutic effectiveness among patients with hormone-receptor positive (HR)+/HER2- advanced breast cancer (aBC).Org: ConcertAI, Perelman School of Medicine, University of Pennsylvania,
Abstract
Identifying and addressing barriers to screening mammography in a medically underserved community.Org: Hospital of the University of Pennsylvania, University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania Health System,
Abstract
Health equity challenges facing testing, evaluation, and implementation of multi-cancer early detection tests.Org: University of Chicago, University of Washington and Fred Hutchinson Cancer Research Centre, Perelman School of Medicine, University of Pennsylvania, Milken Institute School of Public Health,
Abstract
A retrospective chart review of palliative care consultation during curative-intent chemoradiation for head and neck cancer.Org: Temple University Hospital, Philadelphia, PA, Philadelphia, PA, Perelman School of Medicine, Fox Chase Cancer Center, Beth Israel Deaconess Medical Center,
Abstract
Barriers and facilitators to discussion of cancer clinical trials: A qualitative study.Org: Perelman School of Medicine at the University of Pennsylvania, Association of Community Cancer Centers (ACCC), Rockville, MD, Ann B. Barshinger Cancer Institute, Penn Medicine at Lancaster General Health, University of Michigan,
Abstract
Serum IL-6 levels following siltuximab administration in Castleman disease.Org: Perelman School of Medicine at the University of Pennsylvania, University of Pennsylvania, University of Arkansas for Medical Sciences (UAMS), Department of Medicine, Icahn School of Medicine at Mount Sinai, Perelman School of Medicine,
Abstract
Barriers and facilitators to enrolling in a cancer clinical trial financial reimbursement program.Org: Penn Medicine Abramson Cancer Center, Lazarex Cancer Foundation, University of Pennsylvania School of Medicine, Perelman School of Medicine, Abramson Cancer Center at the University of Pennsylvania,